Literature DB >> 1415427

Low-dose aspirin inhibits lipid peroxides and thromboxane but not prostacyclin in pregnant women.

S W Walsh1, Y Wang, H H Kay, M C McCoy.   

Abstract

OBJECTIVE: Preeclampsia is associated with an imbalance of increased thromboxane and decreased prostacyclin and an abnormal increase of lipid peroxides. Lipid peroxides are toxic compounds that damage cells and inhibit prostacyclin synthesis. Low-dose aspirin therapy reduces the incidence of preeclampsia, presumably by selective inhibition of thromboxane to restore a balance between thromboxane and prostacyclin. However, the effectiveness of low-dose aspirin might also relate to inhibition of lipid peroxides. STUDY
DESIGN: To test this hypothesis, 10 women at risk of preeclampsia were placed on low-dose aspirin therapy (81 mg/day) between 9 and 34 weeks of gestation. Plasma samples were collected before and after 3 to 4 days and 3 to 4 weeks of aspirin therapy. Samples were analyzed for thromboxane and prostacyclin by radioimmunoassay of their stable metabolites, thromboxane B2 and 6-keto-prostaglandin F1 alpha, and for lipid peroxides by hydrogen peroxide equivalents.
RESULTS: Low-dose aspirin significantly decreased (p < 0.05) both lipid peroxides (130 +/- 18 vs 92 +/- 11 and 68 +/- 9 nmol/ml, mean +/- SE) and thromboxane (502 +/- 67 vs 138 +/- 67 and 8 +/- 5 pg/ml), but it did not affect prostacyclin (55 +/- 10 vs 41 +/- 8 and 40 +/- 11 pg/ml, p > 0.1).
CONCLUSION: Low-dose aspirin selectively inhibits both lipid peroxides and thromboxane without affecting prostacyclin. Inhibition of both lipid peroxides and thromboxane by low-dose aspirin reveals a new mechanism of action and may account for its effectiveness in the prevention of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1415427     DOI: 10.1016/s0002-9378(12)80013-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Placental Production of Eicosanoids and Sphingolipids in Women Who Developed Preeclampsia on Low-Dose Aspirin.

Authors:  Scott W Walsh; Daniel T Reep; S M Khorshed Alam; Sonya L Washington; Marwah Al Dulaimi; Stephanie M Lee; Edward H Springel; Jerome F Strauss; Daniel J Stephenson; Charles E Chalfant
Journal:  Reprod Sci       Date:  2020-06-17       Impact factor: 3.060

Review 2.  Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?

Authors:  Scott W Walsh; Jerome F Strauss
Journal:  Am J Obstet Gynecol       Date:  2022-02       Impact factor: 8.661

3.  Aspirin-Mediated Reset of Preeclamptic Placental Stem Cell Transcriptome - Implication for Stabilized Placental Function.

Authors:  Matthew P Romagano; Lauren S Sherman; Bobak Shadpoor; Markos El-Far; Sami Souayah; Sri Harika Pamarthi; Joshua Kra; Anupama Hood-Nehra; Jean-Pierre Etchegaray; Shauna F Williams; Pranela Rameshwar
Journal:  Stem Cell Rev Rep       Date:  2022-07-31       Impact factor: 6.692

Review 4.  Aspirin for the prevention and treatment of pre-eclampsia: A matter of COX-1 and/or COX-2 inhibition?

Authors:  Katrina M Mirabito Colafella; Rugina I Neuman; Willy Visser; A H Jan Danser; Jorie Versmissen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2019-09-11       Impact factor: 4.080

5.  [Use of aspirin 100 mg / day to prevent Preeclampsia, in high risk pregnancies, in a cohort from Argentina].

Authors:  Walter Gaston Espeche; Julian Minetto; Martin Rogelio Salazar
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2022-03-07

Review 6.  The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta.

Authors:  Scott W Walsh; Jerome F Strauss
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.